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Abstract: The B cell-depleting IgG1 monoclonal antibody rituximab can persistently suppress disease pro-
gression in some patients with autoimmune diseases. However, the mechanism underlying these long-term
beneficial effects has remained unclear. Here, we evaluated Ig gene usage in patients with anti-myelin-
associated glycoprotein (anti-MAG) neuropathy, an autoimmune disease of the peripheral nervous system
that is mediated by IgM autoantibodies binding to MAG antigen. Patients with anti-MAG neuropathy
showed substantial clonal expansions of blood IgM memory B cells that recognized MAG antigen. The
group of patients showing no clinical improvement after rituximab therapy were distinguished from clin-
ical responders by a higher load of clonal IgM memory B cell expansions before and after therapy, by
persistence of clonal expansions despite efficient peripheral B cell depletion, and by a lack of substantial
changes in somatic hypermutation frequencies of IgM memory B cells. We infer from these data that
the effectiveness of rituximab therapy depends on efficient depletion of noncirculating B cells and is as-
sociated with qualitative immunological changes that indicate reconfiguration of B cell memory through
sustained reduction of autoreactive clonal expansions. These findings support the continued development
of B cell-depleting therapies for autoimmune diseases.
DOI: 10.1172/JCI58743
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Results






















Ig gene repertoire analysis in patients 
with anti-MAG neuropathy before and 
12 months after rituximab-mediated 
B cell depletion. Igh gene variable (V) 
region (A), diversity (D) region (B), 
and joining (J) region (C) repertoires 
in single cell–sorted naive B cells 
(CD19+CD27–IgM+), IgM memory B cells 
(CD19+CD27+IgM+), and IgG memory B 
cells (CD19+CD27+IgG+). Samples were 
analyzed before and 12 months after 
therapy with rituximab and placebo (nor-
mal saline solution). Clonally expanded 
sequences were counted as 1 sequence. 
Numbers within circles indicate the num-
ber of individual sequences analyzed 
per patient cohort and time point. Data 
for each individual donor are provided in 
Supplemental Figures 2–4. The 2-tailed 
Fisher exact test was used to evaluate 
VH, DH, and JH repertoires.
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myelin  in  a  concentration-dependent manner  (Figure  3C). 







CDR3 length and CDR3 pI before 
and after rituximab therapy. The 
same number of individual Igh gene 
sequences as in Figure 1 were ana-
lyzed, and results are displayed 
as data derived from individual 
sequences. Data points represent 
individual sequences; horizontal 
bars and error bars indicate mean 
± SEM. The unpaired Student’s 
t test was used to evaluate CDR3 
lengths and pIs.
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Persistence of clonally expanded IgM memory B cells is associated with 
































Size and antigen specificities of clonal IgM memory B cell expansions. (A) Frequency of clonally expanded IgM memory B cells in patients with 
anti-MAG neuropathy before and after rituximab therapy compared with the IgG memory compartment. Before therapy, data from all study sub-
jects were included. Post-treatment data refer to those patients that received rituximab therapy. Numbers within circles indicate the number of 
individual sequences analyzed per patient cohort and time point. (B) IgM memory B cell clonal expansions before and after therapy in patients 
treated with placebo versus rituximab. Results are based on the analysis of individual sequences in both clinical subgroups. The 2-tailed Fisher 
exact test was used to compare proportions of clonal expansions. (C) Specificity of IgM memory B cell expansions, as assessed by ELISA. 
Recombinant antibodies expressed from highly expanded sequences (see Figure 5B) were tested for binding to purified MAG protein, SGPG, 
and EBNA1. Shown are OD values from the positive control (PC) provided by the manufacturer, a secondary antibody control (2°), an antibody 
(8-18C5) that recognizes myelin oligodendrocyte glycoprotein (MOG) to control for antigen specificity, and recombinantly expressed antibodies 
from patients (P) with anti-MAG neuropathy.
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Demographical and clinical characteristics of patients analyzed in 
this study
Patient	 Clinical	 Age	 Sex	 Disease	 INCAT	score,	leg	
	 subgroup	 (yr)	 	 duration	(yr)
	 	 	 	 	 Baseline	 8	months
P8 Placebo 70 M 18 1 1
P9 Placebo 56 F 10 1 1
P11 Placebo 69 F 21 1 1
P13 Placebo 73 F 8 2 2
P16 Placebo 68 F 8 3 3
P21 Placebo 53 M 7 1 1
P3 Responder 61 M 7 2 1
P14 Responder 72 F 16 2 1
P15 Responder 69 M 9 1 0
P27 Responder 71 M 15 4 1
P5 Nonresponder 70 F 15 3 3
P6 Nonresponder 64 M 12 2 4
P10 Nonresponder 73 M 9 1 1
P12 Nonresponder 69 M 5 0 0
P17 Nonresponder 59 M 6 1 1
P18 Nonresponder 76 M 13 1 1
P22 Nonresponder 76 M 7 1 1
P23 Nonresponder 71 M 11 1 1
P26 Nonresponder 47 M 6 1 1
The primary outcome of the clinical trial was a change of at least 1 
point in INCAT disability scale score in the lower extremities at month 
8. This validated scale measures leg disability as follows: 0, walking not 
affected; 1, walking affected, but walks independently outdoors; 2, uses 
unilateral support (cane, single crutch); 3, uses bilateral support (cane, 
crutches); 4, uses wheelchair, but able to stand and walk a few steps 
with support; 5, restricted to wheelchair. Scoring was done by the same 
neurologist for the same patient throughout the study (11).
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CDR3 length and pI before and 
after rituximab therapy in clinical 
responders and nonresponders. 
Patients showing a clinical improve-
ment after rituximab therapy were 
classified as clinical responders; 
patients with stable or worsened 
disease severity were classified as 
clinical nonresponders. The same 
number of individual Igh gene 
sequences derived from rituximab-
treated patients as in Figure 2 were 
analyzed; results are displayed as 
pooled data derived from individual 
sequences. Data points represent 
individual sequences; horizon-
tal bars and error bars indicate 
mean ± SEM. The unpaired Stu-
dent’s t test was used to evaluate 
Igh characteristics.
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Higher load of IgM memory B cell expansions and persistence of expanded IgM memory B cells is associated with a poor clinical response to 
rituximab. (A) IgM memory expansions before and after rituximab therapy in pooled samples from clinical responders and nonresponders. Results 
are based on the analysis of individual sequences in both clinical subgroups. Numbers within circles indicate the number of individual sequences 
analyzed per patient cohort and time point. The 2-tailed Fisher exact test was used to compare proportions of clonal expansions. (B) IgM mem-
ory B cell expansions in individual clinical responders or nonresponders compared with placebo-treated patients. Gray shading, nonexpanded 
sequences; differently colored shading, clonally expanded CDR3 sequences; black shading, sequences detected before and after therapy in indi-
vidual patients are highlighted in black. Circles denote expanded sequences that were resurrected as IgG monoclonal antibodies (see Figure 3B). 
Due to the low frequency of memory B cells in 2 post-treatment samples, we were not able to amplify PCR products (ND, not determined).
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Lack of change in SHM frequencies in IgM memory B cells is associated with a poor clinical response to rituximab. (A) Mean SHM frequencies of 
IgM memory B cells in framework and CDR regions (FWR1, CDR1, FWR2, CDR2, and FWR3) in placebo-treated patients and in clinical respond-
ers and nonresponders before and after rituximab therapy. (B) Mean SHM frequencies before and after rituximab therapy in clinical responders 
versus nonresponders. Expanded sequences were taken into account only once in order to analyze SHM frequencies in IgM memory B cells 
independent from clonal expansions. Results are based on the analysis of individual sequences in clinical subgroups. The unpaired Student’s t 
test was used to compare SHM frequencies.
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